OncoMatch/Clinical Trials/NCT07634471
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Is NCT07634471 recruiting? Yes, currently enrolling (Jul 2026). This Phase 2/3 trial studies multiple treatments for follicular lymphoma.
Treatment: MK-1045 · Rituximab · Rituximab biosimilar · Bendamustine · Cyclophosphamide · Vincristine · Prednisone · Prednisolone · Doxorubicin Hydrochloride — Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 expression
Required: CD20 expression
Disease stage
Required: Stage II, III, IV
Prior therapy
Cannot have received: systemic anticancer therapy for follicular lymphoma
Cannot have received: radiotherapy for follicular lymphoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- SCRI Oncology Partners ( Site 7000) · Nashville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07634471 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Does this trial require CD20?
Yes, CD20 expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages